{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:27:05Z","timestamp":1769974025144,"version":"3.49.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejmech.2018.03.032","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T03:51:11Z","timestamp":1521258671000},"page":"757-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Design and synthesis of aryloxypropanolamine as \u03b23-adrenergic receptor antagonist in cancer and lipolysis"],"prefix":"10.1016","volume":"150","author":[{"given":"Jiyu","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-9200","authenticated-orcid":false,"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.03.032_bib1","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.032_bib2","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/ijc.21723","article-title":"The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB\/c nude mice is inhibited by beta-blockers","volume":"118","author":"Palm","year":"2006","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2018.03.032_bib3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/SLA.0b013e318211d7b5","article-title":"Improving postoperative immune status and resistance to cancer metastasis a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses","volume":"253","author":"Goldfarb","year":"2011","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejmech.2018.03.032_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1349-7006.2002.tb01313.x","article-title":"Psychosocial stress augments tumor development through beta-adrenergic activation in mice","volume":"93","author":"Hasegawa","year":"2002","journal-title":"Jpn. J. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.032_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4049\/jimmunol.0903301","article-title":"Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a Cyclooxygenase-2 inhibitor","volume":"184","author":"Glasner","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2018.03.032_bib6","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-08-2966","article-title":"Surgical stress promotes tumor growth in ovarian carcinoma","volume":"15","author":"Lee","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.032_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.032_bib8","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1074\/jbc.270.18.10952","article-title":"Long term phorbol ester treatment down-regulates the beta 3-adrenergic receptor in 3T3-F442A adipocytes","volume":"270","author":"Feve","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.032_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A\u00a0switch from white to Brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2018.03.032_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2018.03.032_bib11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1476-5381.1996.tb15294.x","article-title":"Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A","volume":"117","author":"De","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.03.032_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-3565(24)34946-8","article-title":"Potent and selective human \u03b23-adrenergic receptor antagonists","volume":"290","author":"Candelore","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T21:14:35Z","timestamp":1751490875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418302757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":12,"alternative-id":["S0223523418302757"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.032","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of aryloxypropanolamine as \u03b23-adrenergic receptor antagonist in cancer and lipolysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}